Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 20;37(1):1-4.
doi: 10.4274/tjh.galenos.2019.2019.0157. Epub 2019 Sep 2.

Acute Graft-Versus-Host Disease: A Brief Review

Elifcan Aladağ  1 , Engin Kelkitli  2 , Hakan Göker  1
Affiliations
Review

Acute Graft-Versus-Host Disease: A Brief Review

Elifcan Aladağ et al. Turk J Haematol. .

Abstract
in English, Turkish

Graft‐versus‐host disease (GvHD) is an important complication that can be observed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Acute GvHD (aGvHD) is seen after allo-HSCT and the incidence of aGvHD is around 30%-50%. aGvHD prophylaxis is essential in patients undergoing allo-HSCT. Initial therapy for aGvHD is steroids. Prognosis is poor in aGvHD patients not responding to steroids. In this article, the pathobiology, clinical findings, prophylaxis, and treatment of aGvHD will be summarized.

Akut graft‐versus‐host hastalığı (GvHD), allojeneik hematopoetik kök hücre nakli (alloHKHN) sonrasında görülebilen önemli bir komplikasyondur. Akut GvHD (aGvHD) insidansı yaklaşık %30-50 oranında görülmektedir. AlloHKHN yapılan hastalarda GvHD proflaksisi önemlidir. aGvHD gelişen hastalarda başlangıç tedavisi steroiddir. Steroide yanıtsız aGvHD’de prognoz kötüdür. Bu yazıda aGvHD patobiyolojisi, klinik bulguları, profilaksisi ve tedavisi özetlenecektir.

Keywords: Graft-versus-host disease; Acute; Chronic.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

References

    1. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296–307. - PMC - PubMed
    1. Lee SE, Cho BS, Kim JH, Yoon JH, Shin SH, Yahng SA, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW. Risk and prognostic factors for acute GVHD based on NIH consensus criteria. Bone Marrow Transplant. 2013;48:587–592. - PubMed
    1. Chao NJ. Graft-versus-host disease: the viewpoint from the donor T cell. Biol Blood Marrow Transplant. 1997;3:1–10. - PubMed
    1. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol. 2001;29:259–277. - PubMed
    1. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966;62:21–78. - PubMed

LinkOut - more resources